Do analysts prefer APM or MDCX?

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,619.03%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Aptorum Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation and earnings, APM or MDCX?

Aptorum Group has higher revenue and earnings than Medicus Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group $430K 9.86 -$1.36M N/A N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is APM or MDCX more profitable?

Aptorum Group's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Medicus Pharma N/A -3,137.84% -311.33%

Do analysts prefer APM or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, APM or ZIVO?

Aptorum Group has higher revenue and earnings than ZIVO Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group $430K 9.86 -$1.36M N/A N/A ZIVO Bioscience $15.85K 1,069.04 -$7.78M -$1.71 N/A

Is APM or ZIVO more profitable?

Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A ZIVO Bioscience N/A N/A -2,240.92%

Do analysts prefer CYCN or APM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CYCN or APM?

Aptorum Group has lower revenue, but higher earnings than Cyclerion Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyclerion Therapeutics $2.07M 7.97 -$3.53M -$1.66 N/A Aptorum Group $430K 9.86 -$1.36M N/A N/A

Do analysts rate BFRI or APM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, BFRI or APM?

Aptorum Group has lower revenue, but higher earnings than Biofrontera. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $41.71M 0.36 -$10.54M -$0.97 N/A Aptorum Group $430K 9.86 -$1.36M N/A N/A

Do analysts prefer SCNX or APM?

Scienture presently has a consensus target price of $1.50, indicating a potential upside of 267.65%. Given Scienture's stronger consensus rating and higher possible upside, research analysts clearly believe Scienture is more favorable than Aptorum Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, SCNX or APM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scienture $430K 38.55 -$41.51M -$2.51 N/A Aptorum Group $430K 9.86 -$1.36M N/A N/A

Is SCNX or APM more profitable?

Aptorum Group's return on equity of 0.00% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -56.28% -44.76% Aptorum Group N/A N/A N/A

Aptorum Group (APM) Competitors

$0.67 -0.03 (-4.57%)

Closing price 07/17/2026

Extended Trading

$0.67 0.00 (0.00%)

As of 07/17/2026 07:46 PM Eastern

Compare

APM vs. MDCX, ZIVO, CYCN, BFRI, and SCNX

Should you buy Aptorum Group stock or one of its competitors? Aptorum Group's main competitors and comparable companies include Medicus Pharma (MDCX), ZIVO Bioscience (ZIVO), Cyclerion Therapeutics (CYCN), Biofrontera (BFRI), and Scienture (SCNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aptorum Group compare to Medicus Pharma?

Aptorum Group (NASDAQ:APM) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Aptorum Group has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

In the previous week, Medicus Pharma had 1 more articles in the media than Aptorum Group. MarketBeat recorded 1 mentions for Medicus Pharma and 0 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.00 equaled Medicus Pharma'saverage media sentiment score.

Company	Overall Sentiment
Aptorum Group	Neutral
Medicus Pharma	Neutral

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,619.03%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

3.8% of Aptorum Group shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aptorum Group's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Medicus Pharma	N/A	-3,137.84%	-311.33%

Aptorum Group has higher revenue and earnings than Medicus Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Summary

Aptorum Group beats Medicus Pharma on 7 of the 11 factors compared between the two stocks.

How does Aptorum Group compare to ZIVO Bioscience?

Aptorum Group (NASDAQ:APM) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Aptorum Group has higher revenue and earnings than ZIVO Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A
ZIVO Bioscience	$15.85K	1,069.04	-$7.78M	-$1.71	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
ZIVO Bioscience	N/A	N/A	-2,240.92%

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Aptorum Group's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Aptorum Group	Neutral
ZIVO Bioscience	Neutral

Aptorum Group has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market.

Summary

Aptorum Group beats ZIVO Bioscience on 6 of the 8 factors compared between the two stocks.

How does Aptorum Group compare to Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and Aptorum Group (NASDAQ:APM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 64.0% of Aptorum Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cyclerion Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aptorum Group has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Aptorum Group's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%
Aptorum Group	N/A	N/A	N/A

In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Aptorum Group. MarketBeat recorded 1 mentions for Cyclerion Therapeutics and 0 mentions for Aptorum Group. Cyclerion Therapeutics' average media sentiment score of 3.00 beat Aptorum Group's score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclerion Therapeutics	Very Positive
Aptorum Group	Neutral

Aptorum Group has lower revenue, but higher earnings than Cyclerion Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$2.07M	7.97	-$3.53M	-$1.66	N/A
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A

Summary

Aptorum Group beats Cyclerion Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Aptorum Group compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Aptorum Group (NASDAQ:APM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Comparatively, 64.0% of Aptorum Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Biofrontera had 2 more articles in the media than Aptorum Group. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Aptorum Group. Biofrontera's average media sentiment score of 1.00 beat Aptorum Group's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Positive
Aptorum Group	Neutral

Aptorum Group has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Aptorum Group's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Aptorum Group	N/A	N/A	N/A

Biofrontera has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Aptorum Group has lower revenue, but higher earnings than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.36	-$10.54M	-$0.97	N/A
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A

Summary

Biofrontera beats Aptorum Group on 7 of the 13 factors compared between the two stocks.

How does Aptorum Group compare to Scienture?

Scienture (NASDAQ:SCNX) and Aptorum Group (NASDAQ:APM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Scienture's average media sentiment score of 0.00 equaled Aptorum Group'saverage media sentiment score.

Company	Overall Sentiment
Scienture	Neutral
Aptorum Group	Neutral

Scienture presently has a consensus target price of $1.50, indicating a potential upside of 267.65%. Given Scienture's stronger consensus rating and higher possible upside, research analysts clearly believe Scienture is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	38.55	-$41.51M	-$2.51	N/A
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A

Aptorum Group's return on equity of 0.00% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-56.28%	-44.76%
Aptorum Group	N/A	N/A	N/A

Scienture has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

5.7% of Scienture shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 21.4% of Scienture shares are held by company insiders. Comparatively, 64.0% of Aptorum Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Scienture beats Aptorum Group on 6 of the 10 factors compared between the two stocks.

Get Aptorum Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APM vs. The Competition

Export

Metric	Aptorum Group	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.24M	$11.92B	$7.05B	$12.94B
Dividend Yield	N/A	2.69%	2.58%	10.06%
P/E Ratio	N/A	786.05	268.69	24.87
Price / Sales	9.86	744.56	586.52	95.58
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	0.31	10.24	11.29	6.44
Net Income	-$1.36M	$2.78B	$3.44B	$347.05M
7 Day Performance	N/A	0.93%	2.23%	1.00%
1 Month Performance	-91.60%	-1.28%	-0.21%	-0.59%
1 Year Performance	-95.30%	183.18%	75.56%	22.26%

Aptorum Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APM Aptorum Group	0.3354 of 5 stars	$0.67 -4.6%	N/A	-94.7%	$4.24M	$430K	N/A	30	High Trading Volume
MDCX Medicus Pharma	1.7462 of 5 stars	$0.30 -1.3%	$9.00 +2,900.0%	-83.7%	$16.94M	N/A	N/A	N/A	Gap Up
ZIVO ZIVO Bioscience	N/A	$4.00 flat	N/A	-72.3%	$16.61M	$15.85K	N/A	10
CYCN Cyclerion Therapeutics	1.5929 of 5 stars	$3.53 +0.6%	N/A	+56.3%	$16.52M	$2.07M	N/A	30	Positive News Earnings Report
BFRI Biofrontera	1.4434 of 5 stars	$1.24 +1.2%	N/A	+27.8%	$15.81M	$41.71M	N/A	70	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APM) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptorum Group (APM) Competitors

APM vs. MDCX, ZIVO, CYCN, BFRI, and SCNX

How does Aptorum Group compare to Medicus Pharma?

Summary

How does Aptorum Group compare to ZIVO Bioscience?

Summary

How does Aptorum Group compare to Cyclerion Therapeutics?

Summary

How does Aptorum Group compare to Biofrontera?

Summary

How does Aptorum Group compare to Scienture?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM vs. The Competition

Aptorum Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptorum Group (APM) Competitors

APM vs. MDCX, ZIVO, CYCN, BFRI, and SCNX

How does Aptorum Group compare to Medicus Pharma?

Which has more volatility and risk, APM or MDCX?

Does the media refer more to APM or MDCX?

Do analysts prefer APM or MDCX?

Do institutionals and insiders hold more shares of APM or MDCX?

Is APM or MDCX more profitable?

Which has stronger valuation and earnings, APM or MDCX?

Summary

How does Aptorum Group compare to ZIVO Bioscience?

Which has higher valuation and earnings, APM or ZIVO?

Do analysts prefer APM or ZIVO?

Is APM or ZIVO more profitable?

Do institutionals and insiders believe in APM or ZIVO?

Does the media favor APM or ZIVO?

Which has more risk & volatility, APM or ZIVO?

Summary

How does Aptorum Group compare to Cyclerion Therapeutics?

Do institutionals & insiders hold more shares of CYCN or APM?

Which has more risk and volatility, CYCN or APM?

Do analysts prefer CYCN or APM?

Is CYCN or APM more profitable?

Does the media prefer CYCN or APM?

Which has better valuation and earnings, CYCN or APM?

Summary

How does Aptorum Group compare to Biofrontera?

Do analysts rate BFRI or APM?

Do insiders and institutionals hold more shares of BFRI or APM?

Does the media prefer BFRI or APM?

Is BFRI or APM more profitable?

Which has more risk & volatility, BFRI or APM?

Which has preferable valuation and earnings, BFRI or APM?

Summary

How does Aptorum Group compare to Scienture?

Does the media prefer SCNX or APM?

Do analysts prefer SCNX or APM?

Which has preferable valuation and earnings, SCNX or APM?

Is SCNX or APM more profitable?

Which has more risk & volatility, SCNX or APM?

Do insiders and institutionals believe in SCNX or APM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM vs. The Competition

Aptorum Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools